The Goldman Sachs Group Has Lowered Expectations for Amicus Therapeutics (NASDAQ:FOLD) Stock Price
Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) had its price objective reduced by stock analysts at The Goldman Sachs Group from $12.00 to $9.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target would indicate a potential upside […]
Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) had its price objective reduced by stock analysts at The Goldman Sachs Group from $12.00 to $9.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target would indicate a potential upside […]
